%0 Journal Article %T Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial %A He, Zhen %A Yang, Xiuli %A Ma, Tianjiang %A Yang, Qiumin %A Zhang, Chenghui %A Chen, Yunfang %A Wang, Pengyuan %A D’Incecco, Armida %A Metro, Giulio %A Uematsu, Shugo %A Wang, Qiming %J Translational Lung Cancer Research %D 2022 %B 2022 %9 %! Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial %K %X %U https://tlcr.amegroups.org/article/view/67536 %V 11 %N 8 %P 1657-1666 %@ 2226-4477